A Phase 3 interventional study of fluid resuscitation and Fluid resuscitation in Survival and Renal Failure, sponsored by University of Zurich. Completed at 1 site in Switzerland. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2010-05-11.
Sponsored by University of Zurich · Phase 3, Interventional, and Treatment
HES 200/0.5 10% is equal to ringers lactat solution.
30 Patients were enrolled to the study, either to the hyperoncotic HES 200/0.5 (10%) group or to the crystalloids only group. After a treatment protocol of 72 hours we collected data about complications like pulmonary failure and abdominal compartment syndrome. Furthermore, we addressed the question of incidence of mortality and renal failure.
1,995 studies on the registry are indexed under Renal Insufficiency; 173 are open to participants now.
This study's enrollment of 28 is below the median of 43 across 1,504 interventional studies indexed under Renal Insufficiency.
Browse Renal Insufficiency studies →University of Zurich is the lead sponsor of 1,030 studies on the registry; 130 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Fluid resuscitation with HES
Drug: fluid resuscitation
Standard treatment
Drug: Fluid resuscitation
fluid resuscitation with HES
Fluid resuscitation in standardized fashion
Intensive care unit mortality
28 days
Time frame: 28 days
fluid amount during the first 72 hours
Fluid resuscitation after burn
Time frame: 28 days
This study is completed, as verified in May 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Zurich